A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: Final 5-year clinical outcomes from the CREATE study

EuroIntervention

Volumn 8, Issue 7, 2012, Pages 815-822

  Han, Ya Ling ^a   Zhang, Lei ^a   Yang, Li Xia ^b   Liu, Hui Liang ^c   Qu, Peng ^d   Li, Wei Min ^e   Jiang, Tie Min ^f   Li, Shu Mei ^g   Jing, Quan Min ^a   Zhang, Quan Yu ^a   Xu, Bo ^h   Li, Yi ^a   Gao, Run Lin ^h  

^a Shenyang Northern Hospital   (China)

^b KUNMING GENERAL HOSPITAL   (China)

^c GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^d DALIAN MEDICAL UNIVERSITY   (China)

^e HARBIN MEDICAL UNIVERSITY   (China)

^f MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^g THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^h FUWAI HOSPITAL   (China)

Author keywords

Biodegradable polymer; CREATE study; Drug eluting stent; Outcome; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; POLYMER; RAPAMYCIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BIODEGRADABLE IMPLANT; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MATERIAL COATING; MULTICENTER STUDY; MULTICENTER STUDY (TOPIC); PATIENT SAFETY; PROPENSITY SCORE; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; ASPIRIN; CARDIOVASCULAR AGENTS; CHINA; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POLYMERS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872143750     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV8I7A124     Document Type: Article

References (32)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-23.
2. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004;364:583-91.
3. Chamié D, Abizaid A, Costa JR Jr, Feres F, Almiro da Silva JF, Mattos LA, Staico R, Costa RA, Abizaid A, Tanajura LF, Sousa AG, Sousa JE. Serial angiographic and intravascular ultrasound evaluation to interrogate the presence of late "catch-up" phenomenon after Cypher® sirolimus-eluting stent implantation. Int J Cardiovasc Imaging. 2011;27:867-74.
4. Kounis NG, Giannopoulos S, Tsigkas GG, Goudevenos J. Eosinophilic responses to stent implantation and the risk of Kounis hypersensitivity associated coronary syndrome. Int J Cardiol. 2012;156:125-32.
5. Nakazawa G, Ladich E, Finn AV, Virmani R. Pathophysiology of vascular healing and stent mediated arterial injury. EuroIntervention. 2008;4:C7-10.
6. Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, Jiang T, Li Z, Zhang H, Li H, Qiu J, Liu Y, Li Y, Chen X, Gao R; CREATE (Multi-Center Registry of Excel Biodegradable Polymer Drug-Eluting Stents) Investigators. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in daily practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv. 2009;2:303-9.
7. Han Y, Jing Q, Li Y, Yang L, Liu H, Shang X, Jiang T, Li Z, Zhang H, Yan G; Multi-Center Registry of EXCEL BiodegrAdable Polymer Drug EluTing Stents (CREATE) investigators. Sustained clinical safety and efficacy of a biodegradable-polymer coated sirolimus-eluting stent in "real-world" practice: three-year outcomes of the CREATE (Multi-Center Registry of EXCEL Biodegradable Polymer Drug Eluting Stents) study. Catheter Cardiovasc Interv. 2012;79:211-6.
8. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51.
9. Thoemmes F. Propensity score matching in SPSS. E-printer on http://arxiv.org/abs/ 1201.6385.
10. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-48.
11. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-31.
12. Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol. 2012;59:2051-7.
13. Yang TH, Kim DI, Jin HY, Cho YW, Chung SR, Kim DK, Kim YB, Jang JS, Kim U, Seol SH, Kim DK, Kim DS. "Angiographic late catch-up" phenomenon after sirolimus-eluting stent implantation. Int J Cardiol. 2012;160:48-52.
14. Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schömig A, Kastrati A. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv. 2009;2:291-9.
15. Assali A, Vaduganathan M, Vaknin-Assa H, Lev EI, Brosh D, Teplitsky I, Bental T, Battler A, Kornowski R. Comparison of late (3-year) registry data outcomes using bare metal versus drug-eluting stents for treating ST-segment elevation acute myocardial infarctions. Am J Cardiol. 2012;109:1563-8.
16. Kalesan B, Pilgrim T, Heinimann K, Rèber L, Stefanini GG, Valgimigli M, da Costa BR, Mach F, Lüscher TF, Meier B, Windecker S, Jüni P. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:977-87.
17. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni M, Wenaweser P, Billinger M, Seiler C, Gay S, Meier B, Pichler WJ, Jüni P, Virmani R, Windecker S. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009;120:391-9.
18. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435-41.
19. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, Kleiman NS; EVENT Registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297:2001-9.
20. Marroquin OC, Selzer F, Mulukutla SR, Williams DO, Vlachos HA, Wilensky RL, Tanguay JF, Holper EM, Abbott JD, Lee JS, Smith C, Anderson WD, Kelsey SF, Kip KE. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358:342-52.
21. Navarese EP, Kubica J, Castriota F, Gibson CM, De Luca G, Buffon A, Bolognese L, Margheri M, Andreotti F, Di Mario C, De Servi S. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention. 2011;7:985-94.
22. Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol. 2010;56:S43-78.
23. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Jüni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet. 2011;378:1940-8.
24. Wykrzykowska J, Serruys P, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, Di Mario C, Van Geuns RJ, Van Es GA, Juni P, Windecker S. The three year followup of the randomised "all- comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS). EuroIntervention. 2011;7:789-95.
25. D'Ascenzo F, Bollati M, Clementi F, Castagno D, Lagerqvist B, de la Torre Hernandez JM, Ten Berg JM, Brodie BR, Urban P, Jensen LO, Sardi G, Waksman R, Lasala JM, Schulz S, Stone GW, Airoldi F, Colombo A, Lemesle G, Applegate RJ, Buonamici P, Kirtane AJ, Undas A, Sheiban I, Gaita F, Sangiorgi G, Modena MG, Frati G, Biondi-Zoccai G. Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol. 2012 Feb 21. [Epub ahead of print]. PMID: 22360945.
26. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007;49:734-9.
27. Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Jüni P, Schömig A, Windecker S, Kastrati A. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33:1214-22.
28. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125:505-13.
29. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fucê G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125:2015-26.
30. Gao RL, Xu B, Lu SZ, Chen JL, Han YL, Chen JZ, Gai LY, Ge JB, Wang WM, Du ZM, Huo Y, Wang LF, Gao W, Chen JY, He B, Jia GL, Yang ZJ, Cao KJ, Li WM, Shen WF, Wan Z, Huang DJ, Zhu GY; CCSR Investigators. Safety and efficacy of the CYPHER select sirolimus-eluting stent in the "real world" - clinical and angiographic results from the China CYPHER Select registry. Int J Cardiol. 2008;125:339-46.
31. Kitahara H, Kobayashi Y, Fujimoto Y, Nakamura Y, Nakayama T, Kuroda N, Himi T, Miyazaki A, Komuro I. Late stent thrombosis in patients receiving ticlopidine and aspirin after sirolimus-eluting stent implantation. Circ J. 2008;72:168-9.
32. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98:352-6.